Conditioning Regimens in Long-Term Pre-Clinical Studies to Support Development of Ex Vivo Gene Therapy: Review of Nonproliferative and Proliferative Changes-Reference-Cited by-同舟云学术

Conditioning Regimens in Long-Term Pre-Clinical Studies to Support Development of Ex Vivo Gene Therapy: Review of Nonproliferative and Proliferative Changes

Published:2021-01-01 Issue:1-2 Volume:32 Page:66-76
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Chanut Franck J.A.¹,Sanvito Francesca²³,Ferrari Giuliana²⁴,Visigalli Ilaria²,Carriglio Nicola²,Hernandez Raisa Jofra²,Norata Rossana²,Doglioni Claudio³⁴,Naldini Luigi²⁴,Cristofori Patrizia²⁵

Affiliation:

1. Formerly GSK David Jack Centre for R&D, Ware, United Kingdom, Currently SANOFI, Alfortville, France

2. San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy

3. Pathology Unit, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Milan, Italy

4. Vita-Salute San Raffaele University, Milan, Italy; and

5. GSK David Jack Centre for R&D, Ware, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2020.135

Reference52 articles.

1. Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group

2. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives

3. Gene therapy clinical trials worldwide to 2017: An update

4. Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Restoring T and B cell generation in X-linked severe combined immunodeficiency mice through hematopoietic stem cells adenine base editing;Molecular Therapy;2024-06

2. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II;Molecular Therapy;2024-03

3. Best Practice in Toxicologic Pathology;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

4. An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model;EMBO Molecular Medicine;2023-03-06

5. Cell therapeutics loaded with drug delivery system technology;Drug Delivery System;2023-01-25